This is an HTML version of an attachment to the Official Information request 'The Health Research Council’s potentially anti-competitive funding policy'.

25 November 2021
Michael MacAskill
Research Director
New Zealand Brain Research Institute
Email: [FYI request #17199 email]
Tēnā koe Michael
Official Information Act request
The Health Research Council of New Zealand (HRC) received the transfer of your email 
request for official information from the Ministry of Health on 4 November 2021. You 
requested the following information under the Official Information Act 1982 (OIA):
The Health Research Council annually publishes guidelines for its funding 
applications. The current guidelines, dated August 2021 state that funded salaries 
“may be increased by a maximum of 3% per annum each year, or by more if 
specific details of expected promotion are provided and fully justified in Section 
4A. Note: the HRC does not consider annual scale increments or across-the-board 
wage increases as promotions.”

Using current University of Otago pay scales as an example, routine annual 
progression along pay scale increments can often exceed 3%. For example, the 
lowest-paid academic salary range is for Assistant Research Fellows. In 2022, a 
person would start at $50892 on Step 1 of that scale. Over the subsequent two 
years of the typical duration of an HRC project, a combination of annual 
progression to Steps 2 and 3 of the scale, along with projected inflation 
adjustment, would result in annual pay rises of 6.8% and 5.8%. As above, the 
HRC does not regard such progression as being due to promotion and hence will 
not fund the full increments in salary, leading to deficits which will compound 
across the multiple years of a contract.  The employer may be bound by existing 
employment contracts to pay the agreed amounts, with the difference therefore 
needing to be sourced from other funds. Alternatively, there may be pressure upon 
precarious HRC-funded researchers to accept lower pay rates than those funded 
by other agencies. Salary-derived overhead funding on grants is also 
correspondingly reduced, compounding the extent to which the research 
organisation must subsidise the cost of the research contract. 

This policy appears to be a clear deviation from the government’s long-standing 
policy of full-cost funding of research, with the research provider, or even 
individual employees, being required to subsidise the cost of a government 
research contract.

Level 1, South Tower, 110 Symonds Street, Auckland 1010, New Zealand
PO Box 5541, Victoria Street West, Auckland 1142, New Zealand
 +64 9 3035200
www.hrc.govt.nz

This HRC policy has been in effect for several years. On behalf of the health 
research community, I have the following questions:

(1) Does this policy indicate that the government is beginning to resile from its 
commitment to the full-cost-recovery funding model of research?

(2) What are the special circumstances that have led to the HRC adopting this 
policy, which does not (currently) appear to have been enacted by other 
government agencies?

(3) The Health Research Council is a dominant purchaser of public-good health 
research, dwarfing other agencies such as private philanthropic health research 
funders. As such, it is in a near-monopsony position, and like any monopsony, 
poses a risk of imposing anti-competitive practices upon its suppliers (research 
organisations). The policy outlined above does indeed seem on the face of it to be 
a clear attempt at price-fixing, enabled by its monopsony power in the public-good 
health research market. 
(i) Before enacting this policy, did the Heath Research Council seek and receive 
any advice from the Commerce Commission on its anti-competitive nature?
(ii) If not, why not?

(4) Will this policy be allowed to continue at HRC, or to be adopted by any other 
government research funder?

The purpose of this letter is to respond to your Official Information Act request pursuant to 
section 15 of the OIA.  We understand that the guidelines referred to in your request are 
the 2022 Programme Application Guidelines, for use with the 2022 Programme Application 
Form.
Question 1: 
Does this policy indicate that the government is beginning to resile from its 
commitment to the full-cost-recovery funding model of research? 

Response:
The HRC cannot respond on behalf of government. 
Question 2: 
What are the special circumstances that have led to the HRC adopting this policy, 
which does not (currently) appear to have been enacted by other government 
agencies? 

Response: 
The HRC’s requirement for proposal budgets to limit annual salary increases 
(excluding promotions) to within 3% has been in place for over 25 years without 
alteration. There are no special circumstances associated with the requirement.
Question 3:
The Health Research Council is a dominant purchaser of public-good health 
research, dwarfing other agencies such as private philanthropic health research 
funders. As such, it is in a near-monopsony position, and like any monopsony, 



poses a risk of imposing anti-competitive practices upon its suppliers (research 
organisations). The policy outlined above does indeed seem on the face of it to be 
a clear attempt at price-fixing, enabled by its monopsony power in the public-good 
health research market. 

(i)
Before enacting this policy, did the Heath Research Council seek 
and receive any advice from the Commerce Commission on its 
anti-competitive nature? 

(ii) 
If not, why not?
Response:
(i) Records related to the HRC process for determining this proposal budget 
requirement, including whether advice was sought from the Commerce 
Commission, are not available, as this requirement has been in place for over 25 
years.  However, we note that the Commerce Act does not apply to a Crown 
corporation unless it is engaged in trade (section 6 Commerce Act 1986).  The 
HRC is not engaged in trade.
(ii) As noted above, we are not able to determine whether advice was sought or not, 
and if not, why, as we no longer have records in relation to this. 
Question 4:
Will this policy be allowed to continue at HRC, or to be adopted by any other 
government research funder?" 

Response:
The HRC is currently aligning its investment mechanisms with the New Zealand 
Health Research Prioritisation Framework and underpinning New Zealand Health 
Research Strategy. Proposal budget requirements will be reviewed as part of 
broader design and implementation of revised investment mechanisms. The HRC 
cannot respond on behalf of the two Ministries we are accountable to, or on behalf 
of other government research funding organisations.
If you are not satisfied with our response, you have the right to seek an investigation and
review by the Ombudsman of this decision. Information about how to make a complaint is
available at www.ombudsman.parliament.nz or freephone 0800 802 602.
Ngā mihi
Signed by: Sunny Collings 
Date & Time: 25 Nov, 2021 16:07:47 NZDT
Professor Sunny Collings
Tāhuhu Rangapū | Chief Executive